HCV-IN-29

• CAT Number: I045889
• CAS Number: 1009119-83-8
• Molecular Formula: C26H32Cl4N6
• Molecular Weight: 570.38
• Purity: ≥95%
• Synonyms: 2-[(2S)-pyrrolidin-2-yl]-5-[4-[4-[2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazole;tetrahydrochloride
• InChI: InChI=1S/C26H28N6.4ClH/c1-3-21(27-13-1)25-29-15-23(31-25)19-9-5-17(6-10-19)18-7-11-20(12-8-18)24-16-30-26(32-24)22-4-2-14-28-22;;;;/h5-12,15-16,21-22,27-28H,1-4,13-14H2,(H,29,31)(H,30,32);4*1H/t21-,22-;;;;/m0..../s1
• InChIKey: AYOXSBJGFNPGNK-VDUNKYASSA-N
• SMILES: C1C[C@H](NC1)C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6.Cl.Cl.Cl.Cl

HCV-IN-29（Cat No.:I045889）is a research-grade small-molecule inhibitor designed to target hepatitis C virus (HCV) replication pathways. Though its precise binding mechanism may vary depending on the viral protein studied, it has shown potential in disrupting viral RNA synthesis and impairing replication complex assembly. HCV-IN-29 is valuable for investigating antiviral strategies, viral life cycle regulation, and host–pathogen interactions in hepatitis C research. It provides a chemical tool to explore drug resistance, combination therapies, and novel targets, supporting the development of next-generation antivirals against HCV infection.